Myxoid liposarcoma
MONDO:0013280A liposarcoma characterized by the presence of round non-lipogenic primitive mesenchymal cells and small signet ring lipoblasts within a myxoid stoma with a branching vascular pattern. This category includes hypercellular lesions with round cell morphology, formerly known as round cell liposarcoma.
Also known as: myxoid/round cell liposarcoma, myxoid liposarcoma, myxoid liposarcoma (morphologic abnormality), Myxoliposarcoma
2838 clinical trials for this condition and its sub-types, 15 tagged with Myxoid liposarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Myxoid liposarcoma
-
Ovarian myxoid liposarcoma 0 trials
-
Genetically modified t cells take on rare sarcomas
Disease control OngoingThis phase 2 trial tests a one-time infusion of a patient's own immune cells that have been genetically modified to recognize and attack cancer cells. It is for people with advanced synovial sarcoma or myxoid liposarcoma whose tumors have a specific marker (MAGE-A4) and who have …
Phase 2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Supercharged immune cells take on Hard-to-Treat cancers
Disease control OngoingThis study tests a new treatment using a patient's own immune cells that are genetically modified to better recognize and attack certain solid tumors. It is for people with advanced cancers like synovial sarcoma that have not responded to other treatments. The goal is to see if t…
Phase 2 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug BTX-A51 tested in rare sarcomas
Disease control OngoingThis early study tests an oral drug called BTX-A51 in 24 people with advanced liposarcoma (a type of fat tissue cancer) that has spread or come back. The main goal is to see if the drug is safe and tolerable at different doses. It focuses on specific genetic subtypes: MDM2-amplif…
Phase 1 • Sponsor: Michael Wagner, MD • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Engineered immune cells take aim at multiple cancers in early trial
Disease control OngoingThis early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …
Phase 1 • Sponsor: USWM CT, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…
Phase 1/2 • Sponsor: Sotio Biotech Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC